Today, Lilly announced that Anat Ashkenazi, the company’s Chief Financial Officer (CFO), has resigned from her position to pursue a career opportunity outside the pharmaceutical industry. David A. Ricks, the Chair and CEO of Lilly, expressed gratitude for Ashkenazi’s 23…
Today, AbbVie announced the first patient has been treated with ABBV-383 in the CERVINO Phase 3 study. ABBV-383 is a bispecific antibody T-cell engager targeting BCMA and CD3, featuring high BCMA-avidity and low-affinity CD3 binding domains. The Phase 3, multicenter,…
Shionogi & Co., Ltd. recently announced that its subsidiary, Qpex Biopharma, Inc., has exercised a $10 million option granted by the Biomedical Advanced Research and Development Authority (BARDA). This additional funding, part of an ongoing partnership with BARDA, aims to…
UCB, a leading global biopharmaceutical company, has announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has rendered a favorable opinion, recommending the authorization for two new device presentations of bimekizumab.…
AbbVie announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of risankizumab (SKYRIZI®) for treating adults with moderately to severely active ulcerative colitis (UC) who…
Integrated Biosciences, a biotechnology company leveraging synthetic biology and machine learning to create next-generation therapeutics for age-related diseases, announced its collaboration with Illumina Ventures Labs. This partnership aims to integrate Integrated Biosciences’ drug discovery engine with Illumina sequencing, providing both…
Roche announced today that James Sabry (born 1958), Head of Roche Pharma Partnering, will be retiring after fourteen years with the company. James Sabry joined Genentech in 2010 as Head of Genentech Partnering. In 2018, he became Head of Pharma…
Legend Biotech, a leading global cell therapy company, has announced the forthcoming presentation of new and updated data from its CARTITUDE clinical development program at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2024 European Hematology…
UCB, a leading global biopharmaceutical company, has announced the publication of results from the Phase 3 BE HEARD I and BE HEARD II trials in The Lancet. These trials evaluated the effectiveness and safety of bimekizumab, an inhibitor of IL-17A…
A global oncology company today announced the presentation of new analyses for BRUKINSA® (zanubrutinib) at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 31 to June 4, 2024. These presentations underscore the efficacy and safety…
Today, Astellas announced the signing of a memorandum of understanding with YASKAWA Electric Corporation (YASKAWA), marking the beginning of discussions toward creating an innovative cell therapy ecosystem. This collaboration aims to merge pharmaceutical and robotics technologies, potentially revolutionizing cell therapy…
AstraZeneca to Establish $1.5 Billion Antibody Drug Conjugates (ADCs) Manufacturing Facility in Singapore AstraZeneca plans to build a $1.5 billion manufacturing facility in Singapore, aimed at enhancing the global supply of its Antibody Drug Conjugates (ADCs). ADCs represent next-generation cancer…